SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2eu9'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1ERR_B_RALB600_1
(ESTROGEN RECEPTOR)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 GLU A 366
LEU A 373
LEU A 445
LEU A 431
LEU A 390
 None
 1.21A 1errB-2eu9A:
undetectable		 1errB-2eu9A:
21.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1HVY_C_D16C416_1
(THYMIDYLATE SYNTHASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 11 PHE A 167
ILE A 188
ASN A 227
ASP A 138
GLY A 142
 None
 1.30A 1hvyC-2eu9A:
undetectable		 1hvyC-2eu9A:
21.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_A_STIA201_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
GLY A 240
LEU A 290
ALA A 319
 None
 1.00A 1iepA-2eu9A:
21.6		 1iepA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
GLY A 240
ALA A 319
 None
 0.78A 1iepB-2eu9A:
21.7		 1iepB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
ALA A 319
 None
 0.53A 1iepB-2eu9A:
21.7		 1iepB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1IEP_B_STIB202_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 VAL A 204
VAL A 220
ILE A 234
LEU A 290
 None
 0.67A 1iepB-2eu9A:
21.6		 1iepB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JU6_A_LYAA317_1
(THYMIDYLATE SYNTHASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 11 PHE A 167
ILE A 188
ASN A 227
ASP A 138
GLY A 142
 None
 1.37A 1ju6A-2eu9A:
undetectable		 1ju6A-2eu9A:
20.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1JU6_D_LYAD315_1
(THYMIDYLATE SYNTHASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 11 PHE A 167
ILE A 188
ASN A 227
ASP A 138
GLY A 142
 None
 1.36A 1ju6D-2eu9A:
undetectable		 1ju6D-2eu9A:
20.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
ALA A 319
 None
 0.59A 1opjA-2eu9A:
13.7		 1opjA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_A_STIA3_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
VAL A 220
LEU A 290
ALA A 319
 None
 0.56A 1opjA-2eu9A:
13.7		 1opjA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_B_STIB4_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
VAL A 220
GLY A 240
ALA A 319
 None
 0.85A 1opjB-2eu9A:
21.3		 1opjB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1OPJ_B_STIB4_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.61A 1opjB-2eu9A:
21.3		 1opjB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1T46_A_STIA3_1
(HOMO SAPIENS V-KIT
HARDY-ZUCKERMAN 4
FELINE SARCOMA VIRAL
ONCOGENE HOMOLOG)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 205
VAL A 220
LEU A 290
 None
 0.77A 1t46A-2eu9A:
22.3		 1t46A-2eu9A:
23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWH_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
GLU A 201
LEU A 205
LEU A 274
HIS A 281
 None
 0.65A 1uwhA-2eu9A:
22.7		 1uwhA-2eu9A:
24.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1UWH_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
LYS A 186
GLU A 201
LEU A 205
LEU A 274
HIS A 281
 None
 0.69A 1uwhB-2eu9A:
22.6		 1uwhB-2eu9A:
24.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2EUF_B_LQQB401_1
(CELL DIVISION
PROTEIN KINASE 6)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 VAL A 170
LYS A 186
VAL A 220
PHE A 236
ASN A 288
LEU A 290
ALA A 319
ASP A 320
 None
 0.64A 2eufB-2eu9A:
30.3		 2eufB-2eu9A:
31.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2FUM_A_MIXA539_1
(PROBABLE
SERINE/THREONINE-PRO
TEIN KINASE PKNB)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
ASP A 283
LYS A 285
ASN A 288
ASP A 320
 None
 0.80A 2fumA-2eu9A:
25.4		 2fumA-2eu9A:
24.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
VAL A 220
ILE A 234
ALA A 319
 None
 0.65A 2gqgB-2eu9A:
24.2		 2gqgB-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_A_STIA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.77A 2hyyA-2eu9A:
22.1		 2hyyA-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_A_STIA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.79A 2hyyA-2eu9A:
22.1		 2hyyA-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_A_STIA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
VAL A 204
VAL A 220
ILE A 234
 None
 0.60A 2hyyA-2eu9A:
22.1		 2hyyA-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_B_STIB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.69A 2hyyB-2eu9A:
22.0		 2hyyB-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_B_STIB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.63A 2hyyB-2eu9A:
22.0		 2hyyB-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_B_STIB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
VAL A 204
VAL A 220
ILE A 234
 None
 0.51A 2hyyB-2eu9A:
22.0		 2hyyB-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
VAL A 220
LEU A 290
ALA A 319
 None
 0.73A 2hyyC-2eu9A:
22.0		 2hyyC-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_C_STIC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
VAL A 220
GLY A 240
LEU A 290
ALA A 319
 None
 1.04A 2hyyC-2eu9A:
22.0		 2hyyC-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_C_STIC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.78A 2hyyC-2eu9A:
22.0		 2hyyC-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
ILE A 234
LEU A 290
ALA A 319
 None
 0.73A 2hyyD-2eu9A:
21.7		 2hyyD-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 VAL A 170
ALA A 184
LYS A 186
GLU A 201
ILE A 234
GLY A 240
LEU A 290
ALA A 319
 None
 1.11A 2oiqA-2eu9A:
22.0		 2oiqA-2eu9A:
25.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
VAL A 220
ILE A 234
LEU A 290
ALA A 319
 None
 0.71A 2pl0A-2eu9A:
21.7		 2pl0A-2eu9A:
24.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
LYS A 186
GLU A 201
ILE A 234
LEU A 290
ALA A 319
 None
 0.80A 2pl0A-2eu9A:
21.7		 2pl0A-2eu9A:
24.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2ZVA_A_1N1A513_1
(TYROSINE-PROTEIN
KINASE LYN)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
ALA A 184
LYS A 186
GLU A 201
VAL A 220
ILE A 234
ALA A 319
 None
 0.79A 2zvaA-2eu9A:
24.5		 2zvaA-2eu9A:
24.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3C7Q_A_XINA1172_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
GLU A 172
ALA A 184
LYS A 186
VAL A 220
GLY A 240
LEU A 290
 None
 1.05A 3c7qA-2eu9A:
21.4		 3c7qA-2eu9A:
24.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3C7Q_A_XINA1172_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
GLY A 163
GLU A 172
ALA A 184
LYS A 186
VAL A 220
LEU A 290
 None
 0.71A 3c7qA-2eu9A:
21.4		 3c7qA-2eu9A:
24.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 10 LEU A 162
VAL A 170
LYS A 186
ILE A 234
VAL A 318
 None
 0.68A 3cs9A-2eu9A:
21.4		 3cs9A-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 10 LEU A 162
VAL A 170
VAL A 220
ILE A 234
VAL A 318
 None
 0.36A 3cs9A-2eu9A:
21.4		 3cs9A-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
GLU A 201
VAL A 204
GLY A 240
LEU A 290
ALA A 319
 None
 1.17A 3cs9A-2eu9A:
21.4		 3cs9A-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
GLU A 201
VAL A 204
ILE A 208
LEU A 290
ALA A 319
 None
 0.91A 3cs9A-2eu9A:
21.4		 3cs9A-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
GLU A 201
VAL A 204
ILE A 208
ALA A 319
 None
 0.64A 3cs9B-2eu9A:
21.6		 3cs9B-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 9 LEU A 162
VAL A 170
LYS A 186
VAL A 220
ILE A 234
LEU A 290
 None
 0.81A 3cs9B-2eu9A:
21.7		 3cs9B-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 9 LEU A 162
VAL A 170
VAL A 220
ILE A 234
LEU A 290
VAL A 318
 None
 0.63A 3cs9B-2eu9A:
21.7		 3cs9B-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
GLU A 201
ILE A 208
HIS A 281
ALA A 319
 None
 0.76A 3cs9C-2eu9A:
21.2		 3cs9C-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_C_NILC600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
GLU A 201
VAL A 204
ILE A 208
ALA A 319
 None
 0.74A 3cs9C-2eu9A:
21.2		 3cs9C-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 9 LEU A 162
VAL A 170
LYS A 186
ILE A 234
VAL A 318
 None
 0.76A 3cs9C-2eu9A:
21.2		 3cs9C-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 9 LEU A 162
VAL A 170
VAL A 220
ILE A 234
VAL A 318
 None
 0.47A 3cs9C-2eu9A:
21.2		 3cs9C-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3CS9_D_NILD600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
VAL A 170
LYS A 186
LEU A 290
 None
 0.77A 3cs9D-2eu9A:
20.5		 3cs9D-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.83A 3gvuA-2eu9A:
21.7		 3gvuA-2eu9A:
23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GVU_A_STIA1001_1
(TYROSINE-PROTEIN
KINASE ABL2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
VAL A 220
LEU A 290
ALA A 319
 None
 0.60A 3gvuA-2eu9A:
21.7		 3gvuA-2eu9A:
23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3HEC_A_STIA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
LYS A 186
GLU A 201
LEU A 205
LEU A 238
 None
 0.46A 3hecA-2eu9A:
25.4		 3hecA-2eu9A:
27.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
GLU A 201
ILE A 208
VAL A 220
LEU A 290
ALA A 319
 None
 0.67A 3ik3A-2eu9A:
21.5		 3ik3A-2eu9A:
23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_A_0LIA1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
ILE A 208
VAL A 220
HIS A 281
LEU A 290
ALA A 319
 None
 0.71A 3ik3A-2eu9A:
21.5		 3ik3A-2eu9A:
23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_A_0LIA1_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.67A 3ik3A-2eu9A:
21.6		 3ik3A-2eu9A:
23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_B_0LIB2_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
GLU A 201
ILE A 208
VAL A 220
HIS A 281
LEU A 290
ALA A 319
 None
 0.69A 3ik3B-2eu9A:
21.3		 3ik3B-2eu9A:
23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3IK3_B_0LIB2_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.66A 3ik3B-2eu9A:
21.3		 3ik3B-2eu9A:
23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_A_STIA2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.73A 3k5vA-2eu9A:
21.2		 3k5vA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_A_STIA2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.58A 3k5vA-2eu9A:
21.2		 3k5vA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_A_STIA2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
VAL A 204
VAL A 220
ILE A 234
 None
 0.42A 3k5vA-2eu9A:
21.2		 3k5vA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_B_STIB2_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.66A 3k5vB-2eu9A:
21.1		 3k5vB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_B_STIB2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
LYS A 186
VAL A 204
ILE A 234
 None
 0.64A 3k5vB-2eu9A:
21.1		 3k5vB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3K5V_B_STIB2_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
VAL A 204
VAL A 220
ILE A 234
 None
 0.55A 3k5vB-2eu9A:
21.1		 3k5vB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LFA_A_1N1A361_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 14)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 8 ALA A 184
LYS A 186
GLU A 201
LEU A 238
 None
 0.37A 3lfaA-2eu9A:
24.8		 3lfaA-2eu9A:
27.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.75A 3ms9A-2eu9A:
21.4		 3ms9A-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
GLY A 240
LEU A 290
ALA A 319
 None
 1.00A 3ms9B-2eu9A:
21.5		 3ms9B-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MS9_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.70A 3ms9B-2eu9A:
21.5		 3ms9B-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_A_STIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.70A 3mssA-2eu9A:
21.5		 3mssA-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
GLY A 240
LEU A 290
ALA A 319
 None
 1.00A 3mssB-2eu9A:
21.5		 3mssB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_B_STIB1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
ALA A 319
 None
 0.57A 3mssB-2eu9A:
21.5		 3mssB-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_C_STIC1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.70A 3mssC-2eu9A:
21.4		 3mssC-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
ALA A 184
GLU A 201
GLY A 240
LEU A 290
ALA A 319
 None
 1.06A 3mssD-2eu9A:
21.4		 3mssD-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
ALA A 184
GLU A 201
ILE A 208
LEU A 290
ALA A 319
 None
 0.77A 3mssD-2eu9A:
21.4		 3mssD-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 VAL A 170
LYS A 186
VAL A 204
ILE A 234
 None
 0.62A 3mssD-2eu9A:
21.4		 3mssD-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 VAL A 170
VAL A 204
VAL A 220
ILE A 234
 None
 0.54A 3mssD-2eu9A:
21.4		 3mssD-2eu9A:
23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
VAL A 220
ALA A 319
 None
 0.47A 3oezA-2eu9A:
21.8		 3oezA-2eu9A:
25.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
VAL A 204
ILE A 234
LEU A 290
ALA A 319
 None
 0.74A 3oezB-2eu9A:
22.2		 3oezB-2eu9A:
25.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
LYS A 186
VAL A 204
ILE A 234
LEU A 290
ALA A 319
 None
 0.85A 3oezB-2eu9A:
22.2		 3oezB-2eu9A:
25.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OXZ_A_0LIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
GLU A 201
ILE A 208
VAL A 220
GLY A 240
HIS A 281
ALA A 319
 None
 0.99A 3oxzA-2eu9A:
21.3		 3oxzA-2eu9A:
23.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 9 LEU A 162
LYS A 186
VAL A 204
ILE A 234
LEU A 290
VAL A 318
 None
 0.87A 3oxzA-2eu9A:
21.3		 3oxzA-2eu9A:
23.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
GLY A 240
ALA A 319
 None
 0.71A 3pyyA-2eu9A:
21.4		 3pyyA-2eu9A:
23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_A_STIA3_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
GLY A 240
LEU A 290
ALA A 319
 None
 1.02A 3pyyA-2eu9A:
21.4		 3pyyA-2eu9A:
23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3PYY_B_STIB4_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
VAL A 220
LEU A 290
ALA A 319
 None
 0.60A 3pyyB-2eu9A:
21.3		 3pyyB-2eu9A:
23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3RGF_A_BAXA465_1
(CYCLIN-DEPENDENT
KINASE 8)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 VAL A 170
ALA A 184
GLU A 201
LEU A 205
PHE A 236
LEU A 274
HIS A 281
ALA A 319
 None
 0.65A 3rgfA-2eu9A:
7.1		 3rgfA-2eu9A:
27.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
ALA A 184
LYS A 186
GLU A 201
ILE A 234
GLY A 240
LEU A 290
 None
 1.29A 3ue4A-2eu9A:
24.3		 3ue4A-2eu9A:
24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WAR_A_NIOA401_1
(CASEIN KINASE II
SUBUNIT ALPHA)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 8 VAL A 170
LYS A 186
PHE A 236
ASP A 320
 None
 0.54A 3warA-2eu9A:
28.7		 3warA-2eu9A:
26.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZE_A_BAXA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
ALA A 184
LYS A 186
GLU A 201
LEU A 205
LEU A 274
HIS A 281
 None
 0.59A 3wzeA-2eu9A:
22.0		 3wzeA-2eu9A:
23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3WZE_A_BAXA1201_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 205
HIS A 281
 None
 0.57A 3wzeA-2eu9A:
22.0		 3wzeA-2eu9A:
23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZOS_A_0LIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 LEU A 162
ALA A 184
LYS A 186
GLU A 201
LEU A 274
HIS A 281
LEU A 290
ALA A 319
 None
 0.76A 3zosA-2eu9A:
20.8		 3zosA-2eu9A:
24.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
LYS A 186
GLU A 201
LEU A 274
HIS A 281
LEU A 290
ALA A 319
 None
 0.71A 3zosB-2eu9A:
20.9		 3zosB-2eu9A:
24.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AG8_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
VAL A 220
LEU A 290
 None
 0.74A 4ag8A-2eu9A:
22.0		 4ag8A-2eu9A:
24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AGC_A_AXIA2000_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 205
 None
 0.58A 4agcA-2eu9A:
21.6		 4agcA-2eu9A:
22.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ASD_A_BAXA1500_1
(VASCULAR ENDOTHELIAL
GROWTH FACTOR
RECEPTOR 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 205
HIS A 281
 None
 0.55A 4asdA-2eu9A:
21.9		 4asdA-2eu9A:
22.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
LYS A 186
GLU A 201
ILE A 234
HIS A 281
LEU A 290
ALA A 319
 None
 0.57A 4c8bA-2eu9A:
21.9		 4c8bA-2eu9A:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
LYS A 186
GLU A 201
LEU A 205
ILE A 234
HIS A 281
ALA A 319
 None
 0.68A 4c8bA-2eu9A:
21.9		 4c8bA-2eu9A:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LYS A 186
GLU A 201
ILE A 234
HIS A 281
LEU A 290
ALA A 319
ASP A 320
 None
 1.13A 4c8bA-2eu9A:
21.9		 4c8bA-2eu9A:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LYS A 186
GLU A 201
LEU A 205
ILE A 234
HIS A 281
ALA A 319
ASP A 320
 None
 1.10A 4c8bA-2eu9A:
21.9		 4c8bA-2eu9A:
24.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4DAJ_B_0HKB2000_2
(MUSCARINIC
ACETYLCHOLINE
RECEPTOR M3,
LYSOZYME)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		3 / 3 ASN A 242
LEU A 267
PHE A 246
 None
 0.82A 4dajB-2eu9A:
1.8		 4dajB-2eu9A:
19.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4I41_A_MIXA500_1
(SERINE/THREONINE-PRO
TEIN KINASE PIM-1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
ASP A 283
LYS A 285
ASN A 288
LEU A 290
ASP A 320
 None
 0.72A 4i41A-2eu9A:
25.1		 4i41A-2eu9A:
25.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4K38_A_SAMA504_0
(ANAEROBIC
SULFATASE-MATURATING
ENZYME
KP18CYS PEPTIDE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 LEU A 271
VAL A 357
ILE A 360
LEU A 448
CYH A 268
 None
 1.16A 4k38A-2eu9A:
undetectable
4k38D-2eu9A:
undetectable		 4k38A-2eu9A:
21.31
4k38D-2eu9A:
10.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4MKC_A_4MKA1503_1
(ALK TYROSINE KINASE
RECEPTOR)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
LEU A 238
LEU A 290
ASP A 320
 None
 0.72A 4mkcA-2eu9A:
22.6		 4mkcA-2eu9A:
23.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4O0S_A_ADNA500_1
(AURORA KINASE A)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 11 LEU A 162
GLY A 163
VAL A 170
ALA A 184
LYS A 186
ASN A 288
ASP A 320
 None
 0.87A 4o0sA-2eu9A:
26.3		 4o0sA-2eu9A:
25.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4O0W_A_ADNA501_1
(AURORA KINASE A)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 LEU A 162
GLY A 163
VAL A 170
ALA A 184
 None
 0.20A 4o0wA-2eu9A:
25.2		 4o0wA-2eu9A:
25.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4OTW_A_DB8A1101_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-3)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
LYS A 186
VAL A 220
LEU A 290
ALA A 319
ASP A 320
 None
 1.05A 4otwA-2eu9A:
20.5		 4otwA-2eu9A:
22.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
LYS A 186
GLU A 201
ILE A 234
LEU A 290
ALA A 319
ASP A 320
 None
 0.69A 4qmnA-2eu9A:
26.6		 4qmnA-2eu9A:
26.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMS_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 11 ALA A 184
GLU A 201
ILE A 234
LEU A 239
LEU A 290
ASP A 320
 None
 0.57A 4qmsA-2eu9A:
26.6		 4qmsA-2eu9A:
26.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMS_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 11 ALA A 184
LYS A 186
ILE A 234
LEU A 239
LEU A 290
ASP A 320
 None
 0.69A 4qmsA-2eu9A:
26.6		 4qmsA-2eu9A:
26.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QRC_A_0LIA802_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 8 LEU A 162
VAL A 170
LYS A 186
HIS A 281
LEU A 290
 None
 1.02A 4qrcA-2eu9A:
7.7		 4qrcA-2eu9A:
26.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TWP_A_AXIA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		9 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLY A 240
ASN A 288
LEU A 290
ALA A 319
ASP A 320
 None
 0.93A 4twpA-2eu9A:
23.7		 4twpA-2eu9A:
25.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TWP_B_AXIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
ASN A 288
LEU A 290
ALA A 319
ASP A 320
 None
 0.71A 4twpB-2eu9A:
23.8		 4twpB-2eu9A:
25.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4TYJ_A_0LIA801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
GLU A 201
ILE A 208
HIS A 281
LEU A 290
ALA A 319
 None
 0.76A 4tyjA-2eu9A:
21.9		 4tyjA-2eu9A:
26.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4UXQ_A_0LIA1752_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 LEU A 162
ALA A 184
GLU A 201
ILE A 208
ALA A 319
 None
 0.52A 4uxqA-2eu9A:
21.7		 4uxqA-2eu9A:
27.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_A_0LIA1776_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
GLU A 201
ILE A 208
LEU A 274
HIS A 281
ALA A 319
 None
 1.10A 4v01A-2eu9A:
21.0		 4v01A-2eu9A:
24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V01_B_0LIB1770_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
GLU A 201
LEU A 274
HIS A 281
ALA A 319
 None
 0.78A 4v01B-2eu9A:
21.5		 4v01B-2eu9A:
24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_A_0LIA1772_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
HIS A 281
ALA A 319
GLY A 322
 None
 1.32A 4v04A-2eu9A:
21.2		 4v04A-2eu9A:
24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4V04_A_0LIA1772_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 VAL A 170
ALA A 184
GLU A 201
LEU A 274
HIS A 281
ALA A 319
 None
 0.88A 4v04A-2eu9A:
21.2		 4v04A-2eu9A:
24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XLI_B_1N1B600_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 LEU A 162
ALA A 184
LYS A 186
GLU A 201
VAL A 220
ILE A 234
LEU A 290
ALA A 319
 None
 0.82A 4xliB-2eu9A:
17.7		 4xliB-2eu9A:
23.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XV2_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 VAL A 170
ALA A 184
LYS A 186
ASP A 320
PHE A 321
 None
 0.72A 4xv2A-2eu9A:
21.6		 4xv2A-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XV2_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
LYS A 186
LEU A 205
ASP A 320
PHE A 321
 None
 0.75A 4xv2B-2eu9A:
22.1		 4xv2B-2eu9A:
24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4ZAU_A_YY3A1101_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 8 LEU A 162
GLY A 163
VAL A 170
ALA A 184
LEU A 238
 None
 0.65A 4zauA-2eu9A:
23.3		 4zauA-2eu9A:
23.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5AJQ_B_DB8B800_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 10 ALA A 184
GLY A 240
LEU A 290
ALA A 319
ASP A 320
 None
 0.88A 5ajqB-2eu9A:
23.4		 5ajqB-2eu9A:
26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CSW_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 VAL A 170
ALA A 184
LYS A 186
LEU A 205
PHE A 321
 None
 0.81A 5cswA-2eu9A:
21.3		 5cswA-2eu9A:
24.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CSW_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 VAL A 170
ALA A 184
LYS A 186
LEU A 205
PHE A 321
 None
 0.80A 5cswB-2eu9A:
21.2		 5cswB-2eu9A:
24.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
ILE A 234
LEU A 238
LEU A 290
ASP A 320
 None
 0.99A 5h2uB-2eu9A:
21.1		 5h2uB-2eu9A:
25.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HI2_A_BAXA801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
LYS A 186
GLU A 201
LEU A 205
LEU A 274
HIS A 281
 None
 0.74A 5hi2A-2eu9A:
22.8		 5hi2A-2eu9A:
24.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IZJ_F_AZ1F2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAR-DAR-DAR)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 GLY A 163
GLY A 165
GLY A 168
VAL A 170
 None
 0.30A 5izjB-2eu9A:
25.6		 5izjB-2eu9A:
23.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IZJ_G_AZ1G2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAR-DAR)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 GLY A 163
GLY A 165
VAL A 170
LYS A 186
 None
 0.43A 5izjA-2eu9A:
25.8		 5izjA-2eu9A:
23.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J5X_B_AZ1B2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAL-DAR-DAR-
DAR-DAR)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 7 GLY A 163
GLY A 165
VAL A 170
LYS A 186
ASP A 320
 None
 0.64A 5j5xA-2eu9A:
25.5		 5j5xA-2eu9A:
23.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L2I_A_LQQA900_1
(CYCLIN-DEPENDENT
KINASE 6)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 GLY A 163
VAL A 170
ALA A 184
VAL A 220
PHE A 236
LEU A 290
ALA A 319
 None
 0.83A 5l2iA-2eu9A:
11.4		 5l2iA-2eu9A:
30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L2T_A_6ZZA900_1
(CYCLIN-DEPENDENT
KINASE 6)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 ALA A 184
VAL A 220
PHE A 236
LEU A 290
ALA A 319
ASP A 320
 None
 0.83A 5l2tA-2eu9A:
11.7		 5l2tA-2eu9A:
30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L2T_A_6ZZA900_1
(CYCLIN-DEPENDENT
KINASE 6)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 GLY A 163
VAL A 170
ALA A 184
VAL A 220
PHE A 236
LEU A 290
ALA A 319
 None
 0.83A 5l2tA-2eu9A:
11.7		 5l2tA-2eu9A:
30.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L94_A_TESA502_1
(CYTOCHROME P450)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 8 ILE A 234
ALA A 235
VAL A 171
HIS A 143
VAL A 170
 None
 1.18A 5l94A-2eu9A:
undetectable		 5l94A-2eu9A:
23.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 10 LEU A 162
VAL A 170
LYS A 186
GLU A 201
ILE A 234
GLY A 240
 None
 0.74A 5mo4A-2eu9A:
7.4		 5mo4A-2eu9A:
22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
ILE A 208
VAL A 220
HIS A 281
ALA A 319
 None
 0.61A 5mo4A-2eu9A:
7.4		 5mo4A-2eu9A:
22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ALA A 184
VAL A 204
ILE A 208
VAL A 220
ALA A 319
 None
 0.65A 5mo4A-2eu9A:
7.4		 5mo4A-2eu9A:
22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 ILE A 208
VAL A 220
HIS A 281
LEU A 290
ALA A 319
 None
 0.75A 5mo4A-2eu9A:
7.4		 5mo4A-2eu9A:
22.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OWR_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 10)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 8 ALA A 184
GLU A 201
LEU A 290
ASP A 320
 None
 0.44A 5owrA-2eu9A:
22.5		 5owrA-2eu9A:
24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCY_A_DB8A401_1
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
GLY A 240
 None
 0.58A 5vcyA-2eu9A:
26.7		 5vcyA-2eu9A:
22.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VCY_A_DB8A401_2
(MEMBRANE-ASSOCIATED
TYROSINE- AND
THREONINE-SPECIFIC
CDC2-INHIBITORY
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 4 VAL A 220
LEU A 238
ASN A 288
ASP A 320
 None
 0.90A 5vcyA-2eu9A:
26.7		 5vcyA-2eu9A:
22.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XDH_C_DAHC60_1
(PUTATIVE CYTOCHROME
C)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 6 HIS A 328
ASN A 277
VAL A 204
LEU A 200
 None
 1.08A 5xdhA-2eu9A:
0.0
5xdhC-2eu9A:
0.0		 5xdhA-2eu9A:
14.38
5xdhC-2eu9A:
14.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5XV7_A_EMHA705_1
(SERINE-ARGININE (SR)
PROTEIN KINASE 1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		6 / 12 LEU A 162
GLY A 163
VAL A 170
ALA A 184
PHE A 236
ALA A 319
 None
 0.53A 5xv7A-2eu9A:
36.7		 5xv7A-2eu9A:
13.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 238
LEU A 290
 None
 0.60A 5y7zA-2eu9A:
25.7		 5y7zA-2eu9A:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 238
LEU A 290
 None
 0.60A 5y7zA-2eu9A:
25.7		 5y7zA-2eu9A:
26.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_B_IREB401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 ALA A 184
LYS A 186
GLU A 201
LEU A 238
GLY A 240
LEU A 290
ASP A 320
 None
 0.90A 5y7zB-2eu9A:
16.6		 5y7zB-2eu9A:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y7Z_B_IREB401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
ALA A 184
LYS A 186
GLU A 201
LEU A 238
LEU A 290
ASP A 320
 None
 0.67A 5y7zB-2eu9A:
16.6		 5y7zB-2eu9A:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y80_A_IREA401_0
(CYCLIN-G-ASSOCIATED
KINASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		9 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
LEU A 238
GLY A 240
LEU A 290
ASP A 320
 None
 0.88A 5y80A-2eu9A:
24.5		 5y80A-2eu9A:
11.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y9M_A_NIOA401_1
(CASEIN KINASE II
SUBUNIT ALPHA')		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 8 LEU A 162
VAL A 170
LYS A 186
PHE A 236
ASP A 320
 None
 0.60A 5y9mA-2eu9A:
27.5		 5y9mA-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5Y9M_X_NIOX401_1
(CASEIN KINASE II
SUBUNIT ALPHA')		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 8 LEU A 162
VAL A 170
LYS A 186
PHE A 236
ASP A 320
 None
 0.60A 5y9mX-2eu9A:
27.5		 5y9mX-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YF9_B_NIOB401_1
(CASEIN KINASE II
SUBUNIT ALPHA')		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 VAL A 170
LYS A 186
PHE A 236
ASP A 320
 None
 0.64A 5yf9B-2eu9A:
27.3		 5yf9B-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YF9_X_NIOX401_1
(CASEIN KINASE II
SUBUNIT ALPHA')		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 9 LEU A 162
VAL A 170
LYS A 186
PHE A 236
ASP A 320
 None
 0.72A 5yf9X-2eu9A:
27.3		 5yf9X-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5YWM_X_NIOX403_0
(CASEIN KINASE II
SUBUNIT ALPHA')		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 VAL A 170
LYS A 186
PHE A 236
ASP A 320
 None
 0.52A 5ywmX-2eu9A:
27.1		 5ywmX-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5ZV2_B_LEVB801_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
GLY A 240
ALA A 319
 None
 0.86A 5zv2B-2eu9A:
21.0		 5zv2B-2eu9A:
12.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6APH_A_ADNA501_1
(ADENOSYLHOMOCYSTEINA
SE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 LEU A 205
GLU A 201
ASP A 320
LEU A 274
PHE A 236
 None
 1.43A 6aphA-2eu9A:
undetectable		 6aphA-2eu9A:
20.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6GBN_B_ADNB501_1
(-)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 LEU A 205
GLU A 201
ASP A 320
LEU A 274
PHE A 236
 None
 1.46A 6gbnB-2eu9A:
undetectable		 6gbnB-2eu9A:
22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6GBN_C_ADNC501_1
(-)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 12 LEU A 205
GLU A 201
ASP A 320
LEU A 274
PHE A 236
 None
 1.46A 6gbnC-2eu9A:
undetectable		 6gbnC-2eu9A:
22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6GIQ_I_PCFI101_0
(CYTOCHROME B-C1
COMPLEX SUBUNIT 1,
MITOCHONDRIAL
CYTOCHROME B-C1
COMPLEX SUBUNIT 9
CYTOCHROME B-C1
COMPLEX SUBUNIT
RIESKE,
MITOCHONDRIAL)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 9 ASP A 224
SER A 223
TYR A 156
GLY A 160
VAL A 170
 None
 1.36A 6giqA-2eu9A:
0.0
6giqE-2eu9A:
0.0
6giqI-2eu9A:
0.0		 6giqA-2eu9A:
22.01
6giqE-2eu9A:
20.59
6giqI-2eu9A:
14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6GIQ_T_PCFT101_0
(CYTOCHROME B-C1
COMPLEX SUBUNIT 1,
MITOCHONDRIAL
CYTOCHROME B-C1
COMPLEX SUBUNIT 9
CYTOCHROME B-C1
COMPLEX SUBUNIT
RIESKE,
MITOCHONDRIAL)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 8 ASP A 224
TYR A 156
GLY A 160
VAL A 170
 None
 1.10A 6giqL-2eu9A:
undetectable
6giqP-2eu9A:
undetectable
6giqT-2eu9A:
undetectable		 6giqL-2eu9A:
22.01
6giqP-2eu9A:
20.59
6giqT-2eu9A:
14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 VAL A 170
ALA A 184
GLU A 201
ILE A 208
VAL A 220
ILE A 234
LEU A 290
ALA A 319
 None
 0.72A 6hd4A-2eu9A:
21.1		 6hd4A-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 VAL A 170
ALA A 184
LYS A 186
GLU A 201
ILE A 208
ILE A 234
LEU A 290
ALA A 319
 None
 0.79A 6hd4A-2eu9A:
21.1		 6hd4A-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
VAL A 220
ILE A 234
LEU A 290
ALA A 319
 None
 0.60A 6hd4B-2eu9A:
21.1		 6hd4B-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		8 / 12 VAL A 170
ALA A 184
LYS A 186
GLU A 201
ILE A 208
ILE A 234
LEU A 290
ALA A 319
 None
 0.82A 6hd4B-2eu9A:
21.1		 6hd4B-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
GLU A 201
VAL A 220
ILE A 234
LEU A 290
ALA A 319
 None
 0.60A 6hd6A-2eu9A:
21.2		 6hd6A-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 VAL A 170
ALA A 184
LYS A 186
GLU A 201
ILE A 234
LEU A 290
ALA A 319
 None
 0.74A 6hd6A-2eu9A:
21.2		 6hd6A-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
GLU A 201
ILE A 208
VAL A 220
LEU A 290
 None
 0.82A 6hd6B-2eu9A:
15.4		 6hd6B-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		7 / 12 LEU A 162
VAL A 170
ALA A 184
LYS A 186
GLU A 201
ILE A 208
LEU A 290
 None
 0.90A 6hd6B-2eu9A:
15.4		 6hd6B-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		4 / 7 VAL A 204
ILE A 234
GLY A 240
ALA A 319
 None
 0.73A 6hd6B-2eu9A:
15.4		 6hd6B-2eu9A:
13.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6R2E_F_FFOF403_0
(THYMIDYLATE SYNTHASE)		 2eu9 DUAL SPECIFICITY
PROTEIN KINASE CLK3
(Homo
sapiens) 		5 / 11 PHE A 167
ILE A 188
ASN A 227
ASP A 138
GLY A 142
 None
 1.37A 6r2eF-2eu9A:
undetectable		 6r2eF-2eu9A:
20.95